Safety and Feasibility of TWIICE Rise - Phase 2

Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age18-70
SponsorTWIICE

About this trial

The aim of this study is to assess the safety and the feasibility of two versions of TWIICE Rise for exoskeleton-assisted ambulation in patients with a spinal cord injury.

This study is done in two phases:

The first phase evaluates the safety and feasibility of TWIICE Rise 0.0 with 5 patients over 6 sessions in clinic. The second phase is being conducted with TWIICE Rise 1.0. This version has potentially improved functionalities based on feedback from Phase 1. Safety and feasibility will be assessed with 10 patients over 10 sessions in different settings (clinic, home, and community environment).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Informed Consent signed by the subject.

Traumatic and non-traumatic SCI

Motor incomplete SCI with Neurological Level of Injury (NLI) C5-L5, or Motor Complete SCI with NLI T1-L5 as determined by the ISNCSCI.

Male and non-pregnant, non-lactating female aged 18 to 70 years old

Disqualifiers

History of severe neurological injuries other than spinal cord injury (e.g., Multiple Sclerosis, Cerebral Palsy, Amyotrophic Lateral Sclerosis, Traumatic Brain Injury, Stroke)

Ability to walk 10 meters without physical assistance of a person

Severe concurrent medical disease, illness, or condition

Systemic or peripheral infection influencing wearing an exoskeleton.

Trial design

Design model

Single group

Treatments tested in this trial

  • TWIICE Rise

    Device

    TWIICE Rise is a lower-limb overground robotic exoskeleton intended for patients with spinal cord injury (SCI). TWIICE Rise is intended to perform ambulatory functions in rehabilitation institutions, home, or community environment under the supervision of a specially trained coach.

Treatment groups

15 Participants
are divided into 1 treatment group
Group A: Exoskeleton assisted ambulationExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

Incidence of (serious) adverse device effects [Safety]

This outcome is commonly used in healthcare for the measurement of patient safety.

Time frame
From enrollment to the end of intervention at 10 weeks
2

Incidence of device deficiencies [Safety]

Device deficiencies will be assessed according to ISO 14155 (any inadequacy of a medical device with respect to its identity, quality, durability, reliability, safety, or performance). All device deficiencies will be prospectively recorded by study personnel in the Case Report Form at each device-use session and via interim reports throughout the 10-week intervention. Incidence is defined as the number of new device deficiencies occurring during the study period per participant and per device-use session

Time frame
From enrollment to the end of intervention at 10 weeks

Secondary outcomes

1

Incidence of (serious) adverse events [Safety]

This outcome is commonly used in healthcare for the measurement of patient safety.

Time frame
From enrollment to the end of intervention at 10 weeks
2

Heart rate (pre-training, when standing, and post-training) [Safety]

Heart rate (beats per minute) will be measured using a wearable heart-rate monitor

Time frame
First four session of each participant at three standardized time points: (1) 1 minute before standing, (2) after 1 minute of supported standing in the device (3) within 1 minute after completion of the training session (post-training)
3

Systolic and diastolic blood pressure (pre-training, when standing, and post-training) [Safety]

Systolic and diastolic blood pressure (mmHg) will be measured using an automated upper-arm blood pressure monitor

Time frame
First four session of each participant at three standardized time points: (1) 1 minute before standing, (2) after 1 minute of supported standing in the device (3) within 1 minute after completion of the training session (post-training)
4

Pain rating and location [Safety]

Used to assess whether training with TWIICE Rise does not cause or exacerbate pain. Pain intensity and location are assessed at the beginning of each session. Pain intensity is evaluated using the Pain Numeric Rating Scale that is a unidimensional measure of pain in adult. The 11-point numeric scale ranges from '0' representing one pain extreme (e.g. "no pain") to '10' representing the other pain extreme (e.g. "pain as bad as you can imagine" or "worst pain imaginable").

Time frame
From enrollment to the end of intervention at 10 weeks

Other outcomes

1

Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) [Satisfaction]

Used to measure user satisfaction from participants and therapists. The Quebec User Evaluation of Satisfaction with assistive Technology (QUEST 2.0) is designed to measure the level of satisfaction and the value people attribute to assistive technologies. It does so using 12 variables which are scored on a 5 point scale in terms of perceived importance and satisfaction. While items 1-8 rate the satisfaction with the device, items 9-12 are for assessing the satisfaction with the service. If the users are not very satisfied with a feature, they are asked to provide specific feedback. The final score is the mean sum scores of all valid responses with a range of 1 (not satisfied at all) to 5 (very satisfied).

Time frame
up to 16 weeks
2

Open-ended questionnaire [Satisfaction]

Used to study design modifications requested by users and clinicians.

Time frame
up to 16 weeks
3

Subjective health-related questionnaire [General Health]

4-item questionnaire to assess potential health-related changes due to regular exoskeleton-assisted ambulation, with a 5-point Likert-scale (1 = 'strongly disagree' and 5 = 'strongly agree').

Time frame
From enrollment to the end of intervention at 10 weeks
4

Psychosocial Impact of Assistive Devices Scales [General Health]

The Psychosocial Impact of Assistive Devices Scales (PIADS) is a 26-item (7-point Likert-Scale), self-report questionnaire designed to assess the effects of an assistive device on functional independence, well-being, and quality of life. It is divided into three subscales: Competence, adaptability and self-esteem. For each of the subscales, typically means are calculated that range from -3 (maximum negative impact) to +3 (maximum positive impact). To have only positive sum scores, the range of the individual scores are shifted to 1 to 7, meaning that sum scores range from 1 \*26 (26, maximum negative impact) to 7 \*26 (182, maximum positive impact). The PIADS is a responsive measure and sensitive to important variables such as the user's clinical condition, device stigma, and functional features of the device. It has been shown to accurately reflect the self-described experiences of people who use assistive devices.

Time frame
From enrollment to the end of intervention at 10 weeks

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

TWIICE

Lead sponsor

Swiss Paraplegic Research, Nottwil

Collaborator